All enrolled sufferers who acquired not less than one dose of zosuquidar or placebo throughout induction had been monitored with the occurrence of adverse events (439 people, 219 on zosuquidar and 210 on placebo). The most typical adverse functions had been associated with the duration of prolonged and significant myelosuppression https://angiotensin-ii-human-acet55432.digiblogbox.com/53531391/the-2-minute-rule-for-atabecestat